Compare · AVTR vs SEER
AVTR vs SEER
Side-by-side comparison of Avantor Inc. (AVTR) and Seer Inc. (SEER): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and SEER operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- AVTR is the larger of the two at $6.62B, about 67.2x SEER ($98.4M).
- Over the past year, AVTR is down 28.0% and SEER is down 18.4% - SEER leads by 9.7 points.
- SEER has been more active in the news (17 items in the past 4 weeks vs 3 for AVTR).
- AVTR has more recent analyst coverage (25 ratings vs 8 for SEER).
- Company
- Avantor Inc.
- Seer Inc.
- Price
- $9.69+5.73%
- $1.80+0.84%
- Market cap
- $6.62B
- $98.4M
- 1M return
- +16.41%
- -4.51%
- 1Y return
- -28.02%
- -18.37%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 3
- 17
- Recent ratings
- 25
- 8
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Seer Inc.
Seer, Inc., a life sciences company, engages in developing and commercializing products for researchers to unlock biological information. The company develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that provides workflow to make proteomic profiling, and the analysis of the samples needed to characterize the nature of the proteome. It intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. Seer, Inc. has a collaboration agreement with Discovery Life Sciences, LLC. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Latest AVTR
- Wolfe Research resumed coverage on Avantor with a new price target
- SEC Form SD filed by Avantor Inc.
- Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
- RBC Capital Mkts resumed coverage on Avantor with a new price target
- Avantor Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Murthy Mala was granted 25,270 shares, increasing direct ownership by 57% to 69,479 units (SEC Form 4)
- Director Lucier Gregory T was granted 25,270 shares and bought $83,200 worth of shares (10,000 units at $8.32), increasing direct ownership by 289% to 34,006 units (SEC Form 4)
- Director Dingemans Simon was granted 25,270 shares, increasing direct ownership by 406% to 31,495 units (SEC Form 4)
- Director Massaro Joseph R was granted 25,270 shares, increasing direct ownership by 48% to 77,408 units (SEC Form 4)
- Director Makin Louise was granted 25,270 shares, increasing direct ownership by 116% to 47,140 units (SEC Form 4)
Latest SEER
- SEC Form DFRN14A filed by Seer Inc.
- Seer Files Definitive Proxy Materials and Mails Letter to Stockholders
- SEC Form DEFA14A filed by Seer Inc.
- SEC Form DEFA14A filed by Seer Inc.
- SEC Form DEFC14A filed by Seer Inc.
- SEC Form DEFC14A filed by Seer Inc.
- Seer Files ITC Complaint Against Nanomics
- SEC Form DFAN14A filed by Seer Inc.
- The Radoff-JEC Group Calls on Seer Inc. and Its Advisors to Reevaluate Its Premium Acquisition Proposal in the Best Interests of All Stockholders
- Seer to Showcase AI-Driven Multi-Cancer Screening Approach and Next-Generation Proteomics Capabilities at ASMS 2026